Trump signs executive measures for pandemic relief, but effects are unclear.
President Trump took executive action this weekend that he said would extend an array of federal pandemic relief, while the United States reached yet another virus milestone: five million cases.
It was not clear, though, what immediate effect the orders he signed would have, if any, or what authority Mr. Trump has to act on his own. Under the Constitution, Congress has control over federal spending, and it appears likely that Mr. Trumps moves to circumvent Congress will be challenged in court.
Mr. Trump signed the orders billed as a federal eviction ban, a payroll tax suspension, relief for student borrowers and $400 a week for the unemployed at a news conference at his private golf club in New Jersey on Saturday. The orders did not include a number of provisions sought in congressional proposals, like aid to small businesses, school systems, and state and local governments.
The action came after two weeks of talks between White House officials and top congressional Democrats failed to reach agreement on a broad relief plan and temporary benefits provided under earlier aid measures expired with no resolution in sight.
Virus cases have surged in recent weeks, particularly in the Sun Belt states and in communities where officials moved quickly to reopen. But the nascent economic recovery from those reopenings has appeared to slow or stall in many areas. And schools across the country are grappling with how and whether to reopen in the fall.
According to a New York Times database, the U.S. leads the world in confirmed cases. Brazil ranks second, with more than three million confirmed cases, and India is third with two million. Public health experts have warned that the actual number of people infected is far greater. Brazil also reached a milestone of 100,000 deaths on Saturday.
At least 161,900 people infected with the virus have died in the U.S. since the pandemic began.
New Zealand on Sunday marked 100 days without any new reported cases of local transmission of the coronavirus, a major milestone as the pandemic continues to devastate countries across the world including neighboring Australia, where recent outbreaks have led to new lockdown measures in Melbourne and broader Victoria State.
New Zealand, a nation of five million people, reported in March that it had stamped out the virus after strict lockdown measures were implemented, and there has been no community transmission since, according to the countrys Health Ministry.
It has been 100 days since the last case of Covid-19 was acquired locally from an unknown source, the ministry said in a statement on Sunday. No additional cases are reported as having recovered, so there are still 23 active cases of Covid-19 in managed isolation facilities.
Public life has resumed for many people in the country, as they eat out at restaurants, socialize at bars, and attend sports and cultural events. However, some experts warn that letting down their guard now could lead to future outbreaks.
Achieving 100 days without community transmission is a significant milestone, said Dr. Ashley Bloomfield, the countrys top health official, said in a statement on Sunday. However, as we all know, we cant afford to be complacent.
We have seen overseas how quickly the virus can re-emerge and spread in places where it was previously under control, he said, and we need to be prepared to quickly stamp out any future cases in New Zealand.
Eight months ago, the new coronavirus was unknown. But to some human immune cells, it was already something of a familiar foe.
A flurry of recent studies has revealed that a large proportion of the population in some places, 20 to 50 percent of people might harbor immunity assassins called T cells that recognize the new coronavirus despite having never encountered it before.
These T cells, which lurked in the bloodstreams of people long before the pandemic began, are most likely stragglers from past scuffles with other related coronaviruses, including four that frequently cause common colds. Its a case of family resemblance: In the eyes of the immune system, germs with common roots can look alike, such that when a cousin comes to call, the body may already have an inkling of its intentions.
The presence of these T cells has intrigued experts, who say it is too soon to tell whether the cells will play a helpful, harmful or entirely negligible role against the current coronavirus.
But should these cross-reactive T cells exert even a modest influence on the bodys immune response, they might make the disease milder and perhaps partly explain why some people who catch the germ become very sick while others are dealt only a glancing blow.
Radhika Kumar goes to work every morning hoping to save lives. As a contact tracer for Los Angeles County, her job, at least on paper, entails phoning people who have tested positive for the coronavirus, along with others they may have exposed, and providing them with guidance on how to isolate so as not to infect others.
If that sounds easy, it is not.
To persuade people to cooperate, she has to get them to trust her. She has to convince them that they might be infected, even if they have no symptoms. She has to let people curse at her and hang up, then she has to call them back the next day.
And if she wants them to heed her advice, she has to listen, really listen, to how scared they are that if they stay home from their jobs, they might not be able to feed their families.
Sometimes it can really get to you, she said. The other day I had one young lady, and she was screaming on the phone, You dont understand I have three kids. I have to go to work.
I kept calling back and calling back, Ms. Kumar said. Im very relentless like that. I thought about it all night what am I going to do? I called her again first thing in the morning, and I was so relieved when she picked up.
Even as officials at the Centers for Disease Control and Prevention continue to tout the effectiveness of contact tracing, and state and local health agencies across the United States deploy new armies of tracers, tracking down everyone with the coronavirus is proving to be a Sisyphean task.
France is imposing a new requirement that people wear face masks outdoors in crowded areas of Paris and other major cities beginning on Monday as the number of coronavirus infections rises at the fastest rate since a national quarantine ended in mid-May.
The country had gotten the number of infections under control, but the pandemic is creeping back, with 2,288 new Covid-19 cases reported on Friday the third consecutive day of sharp increase. In the Paris Ile-de-France region, the rate of infections reached 2.4 percent on Friday, compared with a 1.6 percent national average.
The rise of new clusters has led the government to warn of the possibility of a second wave of infections in the autumn. In an effort to stem the spread of the virus, masks will now be mandatory for people age 11 and above in high-traffic areas, from the tourist havens of Saint Tropez and Biarritz to Pariss Seine river, Montmartre and other popular sites, as well as at outdoor food markets and in Pariss crowded suburbs.
The police will be enforcing the measures which will be in place for at least a month in Paris and are subject to review in other areas with a fine of 135 euros ($159).
The authorities are especially concerned about the popularity of free parties, that have seen hundreds of young people gather in the Parisien woods and other areas, often without wearing masks.
Wearing a mask in crowded enclosed spaces, including museums, shopping malls and on public transportation, has been compulsory in France since mid-July.
Tens of thousands of motorcyclists swarmed the streets of Sturgis, S.D., in the past few days for an annual rally, despite objections from residents and with little regard for the coronavirus.
The herds of people driving recreational vehicles, bikes and classic cars overran every street in town, making little or no effort to keep six feet apart. Few masks could be seen, and free bandannas being passed out were mostly folded, or wrapped around peoples heads.
With temperatures in the low 80s and not much cloud cover, many people sought shade under shopping tents where Screw Covid shirts were sold.
The Sturgis Motorcycle Rally, a 10-day affair that began Friday, is expected to attract roughly 250,000 enthusiasts this year about half the number who attended last year, but a figure that puts it on track to be among the countrys largest public gatherings since the first coronavirus cases emerged.
South Dakota is one of several states that did not impose a lockdown, and state officials have not required residents to wear masks.
Health experts say the coronavirus is less likely to spread outdoors, especially when people wear masks and socially distance. But large gatherings also increase the number of visitors inside restaurants and stores.
A few businesses in Sturgis put up signs limiting the number of customers who could enter, but most did not.
Over the past week, South Dakota has reported an average of 87 new coronavirus cases per day. At least two new virus deaths and 106 new cases were reported on Saturday.
In 2009, when H1N1, better known as swine flu, was stoking fears of a devastating pandemic, a small biotech company named Inovio Pharmaceuticals rushed to create a vaccine. After announcing promising early results, the companys stock soared more than 1,000 percent.
In the years since, Inovio has announced encouraging news about its work on vaccines for malaria, the Zika virus and even a cancer vaccine. The declarations have caused the companys stock price to leap, enriching investors and senior executives.
There is a catch, though: Inovio has never brought a vaccine to market.
Now, Inovio is working on a vaccine for the coronavirus, and a flurry of positive news releases about its funding and preliminary results have helped the company attract money from the U.S. government and investors.
But some scientists and financial analysts question the viability of Inovios technology. While there are some early signs of promise with its vaccine, Inovio has released only bare-bones data from the first phase of clinical trials. It is locked in a legal battle with a key manufacturing partner that claims Inovio stole its technology.
And while the company has said that it is part of Operation Warp Speed the flagship federal effort to quickly produce treatments and vaccines for the coronavirus Inovio is not on the list of companies selected to receive financial support to mass-produce vaccines.
The absence of that funding, coupled with their ongoing litigation, coupled with the need to scale a device, coupled with the absence of complete Phase 1 data, makes people skeptical, said Stephen Willey, an analyst at Stifel, an investment firm.
Inovio could provide an update on its progress with the vaccine when it releases its second-quarter financial results on Monday.
Saudi Aramco, the worlds largest oil company, said on Sunday that its quarterly earnings had plunged more than 73 percent compared with a year ago, as lockdowns imposed to curb the pandemic drastically cut the demand for oil. Despite the steep fall in earnings, to $6.6 billion from $24.7 billion, the company said it would continue paying a quarterly dividend of $18.75 billion nearly all of which will go to the Saudi government.
At least nine people were killed after a fire broke out on Sunday at a hotel in southern India that was being used as a makeshift facility for Covid-19 patients, officials said.
The fire, in the city of Vijayawada, occurred at the Swarna Palace hotel, which was being used to shelter and treat people who had tested positive for the coronavirus.
The police attributed the accident to a short circuit in an air-conditioner on the ground floor. After the blaze broke out early Sunday, panicked patients jumped from balconies on the upper floors and several were injured, according to local news media outlets.
After most of Indias coronavirus restrictions were lifted in recent weeks, infections have surged, leading some states to move patients into hotels and other makeshift health facilities. As of Sunday, Indias health ministry had reported more than two million total infections and nearly 45,000 deaths.
Despite surging coronavirus transmission rates around the United States, the N.F.L. contends that its season will begin, as scheduled, on Sept. 10. But 68 players have opted out of playing, according to the league.
They represent a microcosm of N.F.L. rosters: rookies and veterans, practice-squadders and starters, all of whom decided to lessen one risk while absorbing another. To keep themselves and their families safer, they will sacrifice the chance to compete for a Super Bowl, forgo showcasing themselves for more lucrative contracts and, in some cases, cede starting jobs and roster spots that may or may not be there next season.
Half of the players who opted out are offensive and defensive linemen, who are in closest contact with other players during practices and games. Leo Koloamatangi, an offensive lineman on the Jets who opted out, said he was resigned to contracting the virus had he chosen to play.
Where I play, Im literally bear-hugging another creature on the other side of the ball every single play, Koloamatangi, 26, said in an interview. If that guy has any symptoms, Im going to get them. He added, For myself, I couldnt take those chances.
Koloamatangi said he knew it was unfeasible for the N.F.L. to enter a bubble, as the N.B.A. and N.H.L. have. But he wondered why the N.F.L. had not pushed back camp and the season, or introduce additional safety measures such as gloves, or helmets with masks that would further mitigate his risk of infection.
As it stands, the N.F.L.s testing protocol calls for players to be tested every day for the first two weeks of training camp, and then every other day after that.
Reporting was contributed by Liz Alderman, David Gelles, Heather Murphy, Stanley Reed, Ben Shpigel, Derrick Taylor, Mark Walker, Katherine J. Wu and Ceylan Yeginsu.
Go here to read the rest:
Coronavirus Live Updates: Latest News and Analysis - The New York Times
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments